Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study

Conclusions HCV reactivation occurred in 23% of HCV‐infected patients receiving cancer treatment, and most had an unremarkable clinical course. However, reactivation can affect the cancer treatment plan. Our findings suggest that HCV infection should not contraindicate cancer therapy and infected patients should have access to multiple cancer treatments with close monitoring while receiving regimens associated with HCV reactivation. This article is protected by copyright. All rights reserved.
Source: Hepatology - Category: Internal Medicine Authors: Tags: Viral Hepatitis Source Type: research